Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MC4R | P32245 | 6/20 | 0.57 |
| ▸ | MC1R | Q01726 | 6/20 | 0.57 |
| ▸ | SSTR5 | P35346 | 7/20 | 0.49 |
| ▸ | SSTR4 | P31391 | 6/20 | 0.49 |
| ▸ | SSTR2 | P30874 | 5/20 | 0.49 |
| ▸ | SSTR1 | P30872 | 3/20 | 0.48 |
| ▸ | SSTR3 | P32745 | 2/20 | 0.48 |
| ▸ | IL23R | Q5VWK5 | 3/20 | 0.48 |
| ▸ | TERF2IP | Q9NYB0 | 1/20 | 0.46 |
| ▸ | REN | P00797 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21392264 | 1.00 | MC4R (0.57) | MC4RMC1RSSTR5SSTR4SSTR2 | |
| SCHEMBL21392338 | 0.98 | MC4R (0.57) | MC4RMC1RSSTR5SSTR4SSTR2 | |
| SCHEMBL20362958 | 0.98 | MC4R (0.57) | MC4RMC1RSSTR5SSTR4SSTR2 | |
| SCHEMBL20206296 | 0.94 | MC1R (0.56) | MC4RMC1RIL23R | |
| SCHEMBL20206282 | 0.93 | MC4R (0.55) | MC4RMC1RIL23R | |
| SCHEMBL20363000 | 0.93 | MC4R (0.55) | MC4RMC1R | |
| SCHEMBL21392332 | 0.93 | MC4R (0.55) | MC4RMC1R | |
| SCHEMBL20362979 | 0.93 | MC4R (0.55) | MC4RMC1R | |
| SCHEMBL21392401 | 0.89 | MC4R (0.58) | MC4RMC1RIL23R | |
| SCHEMBL20206176 | 0.89 | MC1R (0.53) | MC4RMC1RIL23RREN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | PALATIN TECHNOLOGIES, INC. (US) | 2020-07-14 | — | — | US | disclosed |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | PALATIN TECHNOLOGIES INC (US) | 2018-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10711039-B2 | Melanocortin receptor-specific peptide with C-terminal naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885SSTR5 38/4885 |
| US-20180148478-A1 | Melanocortin Receptor-Specific Peptide with C-Terminal Naphthylalanine | MC1R, MC3R, MC4R | MC4R 3/4885MC1R 1/4885SSTR5 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.